A61K 40/4244
Enzymes
Official title: {Enzymes}
A61K40/4244 (Enzymes) appears on 289 US grants and 692 published applications in this corpus.
Search patents in A61K- Granted patents
- 289
- Published applications
- 692
- Assignees
- 339
- Inventors
- 1,316
- Latest grant
- 22 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1994 | 1 | 0 |
| 1995 | 0 | 0 |
| 1996 | 1 | 0 |
| 1997 | 1 | 0 |
| 1998 | 1 | 0 |
| 1999 | 0 | 0 |
| 2000 | 1 | 0 |
| 2001 | 1 | 0 |
| 2002 | 2 | 8 |
| 2003 | 2 | 9 |
| 2004 | 1 | 18 |
| 2005 | 3 | 5 |
| 2006 | 3 | 15 |
| 2007 | 3 | 8 |
| 2008 | 3 | 9 |
| 2009 | 4 | 9 |
| 2010 | 8 | 11 |
| 2011 | 5 | 19 |
| 2012 | 5 | 11 |
| 2013 | 14 | 11 |
| 2014 | 9 | 24 |
| 2015 | 9 | 13 |
| 2016 | 17 | 16 |
| 2017 | 11 | 27 |
| 2018 | 12 | 20 |
| 2019 | 10 | 34 |
| 2020 | 18 | 46 |
| 2021 | 18 | 51 |
| 2022 | 19 | 52 |
| 2023 | 19 | 68 |
| 2024 | 40 | 87 |
| 2025 | 28 | 66 |
| 2026 | 20 | 55 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Genetically engineered phagocytes, and related compositions, vectors, methods and systems22 Sep 2026US 12,741,025 B2The Regents of the University of California
- Vaccine and uses thereof in cell therapy18 Aug 2026US 12,708,672 B2Innovative Cellular Therapeutics Holdings, Ltd.
- Enhanced chimeric antigen receptor cells in hypoxic tumor microenvironment18 Aug 2026US 12,709,737 B2Innovative Cellular Therapeutics Holdings, Ltd.
- Compositions and methods regarding engineered and non-engineered γδ T-cells for treatment of solid tumors4 Aug 2026US 12,698,340 B2Adicet Therapeutics, Inc.
- Nant cancer vaccine16 Jun 2026US 12,653,874 B2ImmunityBio, Inc.
- Engineered immune cells for treating cancer in combination with il-2/il-15 receptor beta-gamma agonists24 Sep 2026US 2026/0284145 A1Sotio Biotech Inc.
- Targeted lnp compositions for in vivo immune cell engineering and methods of use thereof17 Sep 2026US 2026/0274918 A1CREATE Medicines, Inc.
- Anti-steap1 car17 Sep 2026US 2026/0274988 A1Oslo Universitetssykehus Hf
- Hla class ii-restricted drb t cell receptors against ras with g12d mutation10 Sep 2026US 2026/0265338 A1The United States of America, as represented by the Secretary, Department of Health and Human Servic
- Methods and materials for treating cancer3 Sep 2026US 2026/0256897 A1Mayo Foundation for Medical Education and Research
Most cited
By later US patents
- Methods related to immunostimulatory nucleic acid-induced interferon110US 6,949,520 B1Coley Pharmaceutical GmbH · 2005
- Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool110US 8,637,307 B2The Trustees of the University of Pennsylvania · 2014
- TADG-15: an extracellular serine protease overexpressed in carcinomas84US 7,291,462 B2The University of Arkansas for Medical Sciences · 2007
- Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool81US 7,745,140 B2The Trustees of the University of Pennsylvania · 2010
- Activation and expansion of T-cells using an engineered multivalent signaling platform69US 7,638,326 B2The Trustees of the University of Pennsylvania · 2009